TCS has put its mark on the highly regulated world of pharma with the introduction of TCS ADD AgentHub, an enterprise AI platform that puts agentic AI to work in clinical trials and drug safety.
It is a case of what happens when artificial intelligence in one of the most tightly controlled industries is asked to do more than just field questions and start getting on with the job. The new offering from Tata Consultancy Services (TCS) is built for pharmaceutical firms to put role-based AI agents into their clinical development and pharmacovigilance operations, all while human oversight and regulatory compliance remain the priority.
TCS’s Human + AI Model Keeps People in Control
The philosophy behind AgentHub is straightforward: let the AI handle the high-volume, repetitive side of things, but leave governance and the final say with people. In pharma, that separation is essential. Processes around clinical and safety matters have to be reproducible, explainable and in line with GxP standards. To that end, AgentHub logs its actions so that workflows are audit-ready and fully traceable.
How AgentHub Could Transform Clinical and Drug Safety Workflows
The platform is meant to be an AI agent layer over TCS’s current TCS ADD portfolio for clinical research, not yet another standalone tool. It can be put to use in a number of areas in drug safety and clinical development, such as:
- ICSR intake, coding, data entry and review
- Study design and protocol digitisation
- Clinical data review and SDTM transformation
- Literature analysis and medical monitoring
- Drug safety case processing
AgentHub’s Reported Efficiency Gains
Given the cost and length of clinical trials, the impact TCS is looking for is considerable. The company reports that solutions powered by AgentHub have shown up to 40% better efficiency in clinical data management and a 30% cut in the effort required to build a clinical study. There are also up to 30% savings to be had in end-to-end safety case processing, and TCS says its AI safety agents have reduced quality-control work by as much as 50%.
Built on Google Cloud’s Gemini Enterprise
Running on Google Cloud’s Gemini Enterprise infrastructure, AgentHub is part of the TCS ADD suite and is set up to slot into the clinical and safety workflows an organisation already has in place. This makes it easier for pharma companies to scale agentic AI without having to tear down and rebuild their systems.
For TCS, the launch is a step away from the chatbots and copilots of the past toward AI agents that can run multi-step workflows. One can imagine agents in pharma eventually taking on the extraction and coding of clinical data or supporting medical teams with literature analysis.
Why Auditability Matters for AI in Pharma
But the question in this industry is never just whether the AI can do the task; it is whether you can prove how it was done. AgentHub is designed to provide that accountability with an inspection-ready approach to audits, giving organisations the documentation regulators want along with the efficiency they need.
Agentic AI Moves From Experiment to the Pharma Enterprise
While TCS has not given details on any specific customer deployments, the platform is open to pharma clients. Its standing will ultimately be judged on how well it integrates with complex systems and holds up under the scrutiny of real-world use. For the time being, it is a good illustration of agentic AI making the transition from experiment to the enterprise floor, where one needs both speed and the means to answer for it.
